Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has received a Complete Response Letter (CRL) from the USFDA regarding their Biologics License Application for a biosimilar rituximab, a result of inspections and application details. The company assures that this will not affect their current commercial products or those in development, and they are committed to working with the USFDA to resolve the issues promptly.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
